Impact of genotypic drug resistance mutations on clinical and immunological outcomes in HIV-infected adults on HAART in West Africa

AIDS

Volumn 21, Issue 9, 2007, Pages 1157-1164

  Seyler, Catherine ^a,c   Adjé Touré, Christiane ^b   Messou, Eugène ^a,d   Dakoury Dogbo, Nicole ^c,d   Rouet, François ^e   Gabillard, Delphine ^a   Nolan, Monica ^b   Toure, Siaka ^a,d   Anglaret, Xavier ^a,c  

^a INSERM   (France)

^b Project RETRO CI Abidjan   (Côte d’Ivoire)

^c Cotrame ANRS 1203 Study Group ^*  (Côte d’Ivoire)

^d ACONDA   (Côte d’Ivoire)

^e CENTRE HOSPITALIER UNIVERSITAIRE DE TREICHVILLE   (Côte d’Ivoire)

Author keywords

Adults; Antiretroviral therapy; HIV; Morbidity; Resistance; Sub Saharan Africa

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE;

ADULT; AFRICA; ARTICLE; CD4 LYMPHOCYTE COUNT; FEMALE; GENE MUTATION; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PRIORITY JOURNAL; VIRUS LOAD;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; COTE D'IVOIRE; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV INFECTIONS; HIV-1; HIV-2; HUMANS; MALE; MUTATION; TREATMENT OUTCOME; VIRAL LOAD;

EID: 34248579283     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3281c615da     Document Type: Article

References (30)

1. UNAIDS. Report on the global AIDS epidemic. Geneva; 2006. Available at: http://www.unaids.org/en/HIV_data/2006Global-Report/default.asp. Accessed: March 2007.
2. Nkengasong JN, Adje-Toure C, Weidle PJ. HIV antiretroviral drug resistance in Africa. AIDS Rev 2004; 6:4-12.
3. Toni T, Masquelier B, Bonard D, Faure M, Huet C, Caumont A, et al. Primary HIV-1 drug resistance in Abidjan (Cote d'Ivoire): a genotypic and phenotypic study. AIDS 2002; 16:488-491.
4. Vergne L, Kane CT, Laurent C, Diakhate N, Gueye NF, Gueye PM, et al. Low rate of genotypic HIV-1 drug-resistant strains in the Senegalese government initiative of access to antiretroviral therapy. AIDS 2003; 17 (Suppl 3):S31-S38.
5. Bellocchi MC, Forbici F, Palombi L, Gori C, Coelho E, Svicher V, et al. Subtype analysis and mutations to antiviral drugs in HIV-1-infected patients from Mozambique before initiation of antiretroviral therapy: results from the DREAM programme. J Med Virol 2005; 76:452-458.
6. Adje C, Cheingsong R, Roels TH, Maurice C, Djomand G, Verbeist W, et al. High prevalence of genotypic and phenotypic HIV-1 drug-resistant strains among patients receiving antiretroviral therapy in Abidjan, Cote d'Ivoire. J Acquir Immune Defic Syndr 2001; 26:501-506.
7. Vergne L, Malonga-Mouellet G, Mistoul I, Maroungou R, Mansaray H, Peeters M, et al. Resistance to antiretroviral treatment in Gabon: need for implementation of guidelines on antiretroviral therapy use and HIV-1 drug resistance monitoring in developing countries. J Acquir Immune Defic Syndr 2002; 29:165-168.
8. Weidle PJ, Malamba S, Mwebaze R, Sozi C, Rukundo G, Douning R, et al. Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients' response, survival, and drug resistance. Lancet 2002; 360:34-40.
9. Seyler C, Anglaret X, Dakoury-Dogbo N, Messou E, Toure S, Danel C, et al. Medium-term survival, morbidity and immunovirological evolution in HIV-infected adults receiving antiretroviral therapy, Abidjan, Cote d'Ivoire. Antivir Ther 2003; 8:385-393.
10. Anglaret X, Messou E, Ouassa T, Toure S, Dakoury-Dogbo N, Combe P, et al. Pattern of bacterial diseases in a cohort of HIV-1 infected adults receiving cotrimoxazole prophylaxis in Abidjan, Cote d'Ivoire. AIDS 2003; 17:575-584.
11. Anglaret X, Dakoury-Dogbo N, Bonard D, Toure S, Combe P, Ouassa T, et al. Causes and empirical treatment of fever in HIVinfected adult outpatients, Abidjan, Cote d'Ivoire. AIDS 2002; 16:909-918.
12. Anglaret X, Toure S, Gourvellec G, Tchehy A, Zio L, Zaho M, et al. Impact of vital status investigation procedures on estimates of survival in cohorts of HIV-infected patients from Sub-Saharan Africa. J Acquir Immune Defic Syndr 2004; 35:320-323.
13. Rouet F, Ekouevi DK, Chaix ML, Burgard M, Inwoley A, Tony TD, et al. Transfer and evaluation of an automated, low-cost real-time reverse transcription-PCR test for diagnosis and monitoring of human immunodeficiency virus type 1 infection in a West African resource-limited setting. J Clin Microbiol 2005; 43:2709-2717.
14. Bile EC, Adje-Toure C, Borget MY, Kalou M, Diomande F, Chorba T, Nkengasong HN. Performance of drug-resistance genotypic assays among HIV-1 infected patients with predominantly CRF02_AG strains of HIV-1 in Abidjan, Cote d'Ivoire. J Clin Virol 2005; 32:60-66.
15. Johnson VA, Brun-Vezinet F, Clotet B, Kuritzkes DR, Pillay D, Schapiro JM, Richman DD. Update of the drug resistance mutations in HIV-1: Fall 2006. Top HIV Med 2006; 14:125-130.
16. Richard N, Juntilla M, Abraha A, Demers K, Paxinos E, Gadovitch J, et al. High prevalence of antiretroviral resistance in treated Ugandans infected with nonsubtype B human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 2004; 20:355-364.
17. Laurent C, Kouanfack C, Vergne L, Tardy M, Zekeng L, Noumsi N, et al. Antiretroviral drug resistance and routine therapy, Cameroon. Emerg Infect Dis 2006; 12:1001-1004.
18. Ferradini L, Jeannin A, Pinoges L, Izopet J, Odhiambo D, Mankhambo L, et al. Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment. Lancet 2006; 367:1335-1342.
19. Zaccarelli M, Tozzi V, Lorenzini P, Trotta MP, Forbici F, Visco-Comandini U, et al. Multiple drug class-wide resistance associated with poorer survival after treatment failure in a cohort of HIV-infected patients. AIDS 2005; 19:1081-1089.
20. Hogg RS, Bangsberg DR, Lima VD, Alexander C, Bonner S, Yip B, et al. Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART. PLoS Med 2006; 3:e356.
21. Lucas GM, Gallant JE, Moore RD. Relationship between drug resistance and HIV-1 disease progression or death in patients undergoing resistance testing. AIDS 2004; 18:1539-1548.
22. Machouf N, Thomas R, Nguyen VK, Trottier B, Boulassel MR, Wainberg MA, Routy JP. Effects of drug resistance on viral load in patients failing antiretroviral therapy. J Med Virol 2006; 78:608-613.
23. Deeks SG, Barbour JD, Martin JN, Swanson MS, Grant RM. Sustained CD4R T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection. J Infect Dis 2000; 181:946-953.
24. Cozzi-Lepri A, Phillips AN, Miller V, Katlama C, Ledergerber B, Vella S, et al. Changes in viral load in people with virological failure who remain on the same HAART regimen. Antivir Ther 2003; 8:127-136.
25. Martinez-Picado J, Savara AV, Sutton L, D'Aquila RT. Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1. J Virol 1999; 73:3744-3752.
26. Deeks SG, Wrin T, Liegler T, Hoh R, Hayden M, Barbour JD, et al. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med 2001; 344:472-480.
27. Ledergerber B, Lundgren JD, Walker AS, Sabin C, Justice A, Reiss P, et al. Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. Lancet 2004; 364:51-62.
28. Kantor R, Shafer RW, Follansbee S, Taylor J, Shilane D, Hurley L, et al. Evolution of resistance to drugs in HIV-1-infected patients failing antiretroviral therapy. AIDS 2004; 18:1503-1511.
29. Goetz MB, Ferguson MR, Han X, McMillan G, St Clair M, Pappa KA, et al. Evolution of HIV resistance mutations in patients maintained on a stable treatment regimen after virologic failure. J Acquir Immune Defic Syndr 2006; 15:541-549.
30. Goldie SJ, Yazdanpanah Y, Losina E, Weinstein MC, Anglaret X, Walensky RP, et al. Cost-effectiveness of HIV treatment in resource-poor settings-the case of Cote d'Ivoire. N Engl J Med 2006; 355:1141-1153.